6-KThe Wire
Sanofi files 6-K
Filed May 27, 2026 · 1mo ago · Accession 0001193125-26-240810
Plain English
Sanofi announced positive Phase 2 data for efdoralprin alfa in AATD, demonstrating superiority over standard-of-care augmentation therapy in achieving higher fAAT levels. (2) * The reporting currency is not stated, and the accounting basis is not stated.
Filing details
- Company
- Sanofi
- Ticker
- SNY
- CIK
- 1121404
- Form type
- 6-K
- Filing date
- May 27, 2026
- Report date
- May 27, 2026
- Document
- d134599d6k.htm
- Size
- 51 KB